BC-ADM (BOARD CERTIFIED – ADVANCED
DIABETES MANAGEMENT) EXAM 2026 |
ACTUAL EXAM Q&A WITH VERIFIED
ANSWERS & DETAILED RATIONALES |
LATEST UPDATED PDF
BC-ADM (BOARD CERTIFIED – ADVANCED DIABETES MANAGEMENT) EXAM 2026
ACTUAL EXAM Q&A WITH VERIFIED ANSWERS & DETAILED EXPERT RATIONALE |
LATEST UPDATED
OVERVIEW
• This material contains 200 high-yield multiple-choice questions with verified
answers and detailed EXPERT RATIONALE designed to simulate the actual BC-ADM
exam experience — use it by testing yourself first before checking the answer and
EXPERT RATIONALE for each question.
• Each question reflects the core BC-ADM competency domains including
pathophysiology, pharmacology, nutrition, technology, complications, and patient
management — ideal for last-minute review or structured study over several
sessions.
Q1. A 52-year-old patient with type 2 diabetes has an HbA1c of 9.2%. The
clinician decides to initiate insulin therapy. Which of the following is the most
appropriate starting insulin regimen?
A. Premixed insulin 70/30 twice daily
B. Rapid-acting insulin before each meal
C. Insulin glargine once daily at bedtime
D. NPH insulin twice daily
E. Insulin detemir three times daily
CORRECT ANSWER: C. Insulin glargine once daily at bedtime
, EXPERT RATIONALE: Insulin glargine (a long-acting basal insulin) once daily is the
recommended starting point for most type 2 diabetes patients initiating insulin. It
provides a stable, peakless insulin level over 24 hours, minimizing hypoglycemia
risk while effectively lowering fasting glucose.
Q2. Which of the following best describes the mechanism of action of GLP-1
receptor agonists?
A. Inhibit hepatic glucose production only
B. Block sodium-glucose cotransporter 2 in the kidneys
C. Stimulate glucose-dependent insulin secretion, suppress glucagon, and slow
gastric emptying
D. Directly stimulate pancreatic beta cells independent of glucose levels
E. Inhibit dipeptidyl peptidase-4 enzyme
CORRECT ANSWER: C. Stimulate glucose-dependent insulin secretion,
suppress glucagon, and slow gastric emptying
EXPERT RATIONALE: GLP-1 receptor agonists mimic the incretin hormone GLP-1.
They enhance insulin secretion in a glucose-dependent manner, suppress
postprandial glucagon, delay gastric emptying, and promote satiety — all
contributing to glycemic control and weight reduction.
Q3. A patient with type 1 diabetes uses a continuous glucose monitor (CGM).
The target time in range (TIR) for glucose values between 70–180 mg/dL is:
A. Greater than 90%
B. Greater than 70%
C. Greater than 50%
D. Greater than 60%
E. Greater than 80%
, CORRECT ANSWER: B. Greater than 70%
EXPERT RATIONALE: International consensus guidelines recommend a TIR of
greater than 70% (i.e., more than 16.8 hours per day) in the 70–180 mg/dL range for
most people with type 1 or type 2 diabetes as a key CGM metric for optimal
glycemic management.
Q4. Which complication is most closely associated with poor glycemic control
in both type 1 and type 2 diabetes?
A. Hypothyroidism
B. Peripheral neuropathy
C. Osteoporosis
D. Anemia of chronic disease
E. Pulmonary hypertension
CORRECT ANSWER: B. Peripheral neuropathy
EXPERT RATIONALE: Diabetic peripheral neuropathy is one of the most common
complications of chronic hyperglycemia. Sustained high glucose levels lead to nerve
damage through mechanisms including polyol pathway activation, oxidative stress,
and advanced glycation end-product accumulation.
Q5. A patient reports blood glucose levels consistently high in the early
morning before breakfast. What phenomenon is most likely responsible?
A. Somogyi effect
B. Insulin waning
C. Dawn phenomenon
D. Reactive hypoglycemia
E. Glucagon rebound
, CORRECT ANSWER: C. Dawn phenomenon
EXPERT RATIONALE: The dawn phenomenon occurs due to overnight surges in
counter-regulatory hormones (growth hormone, cortisol) that increase hepatic
glucose output, causing fasting hyperglycemia. It is distinguished from the Somogyi
effect (rebound from nocturnal hypoglycemia) by the absence of preceding low
glucose values.
Q6. Which of the following SGLT-2 inhibitors has demonstrated cardiovascular
mortality benefit in patients with established cardiovascular disease and type
2 diabetes?
A. Sitagliptin
B. Metformin
C. Empagliflozin
D. Pioglitazone
E. Exenatide
CORRECT ANSWER: C. Empagliflozin
EXPERT RATIONALE: The EMPA-REG OUTCOME trial demonstrated that
empagliflozin significantly reduced cardiovascular death, hospitalization for heart
failure, and major adverse cardiovascular events in patients with type 2 diabetes
and established cardiovascular disease.
Q7. A 45-year-old woman with type 2 diabetes and stage 3 CKD (eGFR 38
mL/min) is currently on metformin. What is the most appropriate action?
A. Continue metformin at full dose
B. Increase metformin dose to improve glycemic control
C. Discontinue metformin due to lactic acidosis risk
D. Switch to insulin only
DIABETES MANAGEMENT) EXAM 2026 |
ACTUAL EXAM Q&A WITH VERIFIED
ANSWERS & DETAILED RATIONALES |
LATEST UPDATED PDF
BC-ADM (BOARD CERTIFIED – ADVANCED DIABETES MANAGEMENT) EXAM 2026
ACTUAL EXAM Q&A WITH VERIFIED ANSWERS & DETAILED EXPERT RATIONALE |
LATEST UPDATED
OVERVIEW
• This material contains 200 high-yield multiple-choice questions with verified
answers and detailed EXPERT RATIONALE designed to simulate the actual BC-ADM
exam experience — use it by testing yourself first before checking the answer and
EXPERT RATIONALE for each question.
• Each question reflects the core BC-ADM competency domains including
pathophysiology, pharmacology, nutrition, technology, complications, and patient
management — ideal for last-minute review or structured study over several
sessions.
Q1. A 52-year-old patient with type 2 diabetes has an HbA1c of 9.2%. The
clinician decides to initiate insulin therapy. Which of the following is the most
appropriate starting insulin regimen?
A. Premixed insulin 70/30 twice daily
B. Rapid-acting insulin before each meal
C. Insulin glargine once daily at bedtime
D. NPH insulin twice daily
E. Insulin detemir three times daily
CORRECT ANSWER: C. Insulin glargine once daily at bedtime
, EXPERT RATIONALE: Insulin glargine (a long-acting basal insulin) once daily is the
recommended starting point for most type 2 diabetes patients initiating insulin. It
provides a stable, peakless insulin level over 24 hours, minimizing hypoglycemia
risk while effectively lowering fasting glucose.
Q2. Which of the following best describes the mechanism of action of GLP-1
receptor agonists?
A. Inhibit hepatic glucose production only
B. Block sodium-glucose cotransporter 2 in the kidneys
C. Stimulate glucose-dependent insulin secretion, suppress glucagon, and slow
gastric emptying
D. Directly stimulate pancreatic beta cells independent of glucose levels
E. Inhibit dipeptidyl peptidase-4 enzyme
CORRECT ANSWER: C. Stimulate glucose-dependent insulin secretion,
suppress glucagon, and slow gastric emptying
EXPERT RATIONALE: GLP-1 receptor agonists mimic the incretin hormone GLP-1.
They enhance insulin secretion in a glucose-dependent manner, suppress
postprandial glucagon, delay gastric emptying, and promote satiety — all
contributing to glycemic control and weight reduction.
Q3. A patient with type 1 diabetes uses a continuous glucose monitor (CGM).
The target time in range (TIR) for glucose values between 70–180 mg/dL is:
A. Greater than 90%
B. Greater than 70%
C. Greater than 50%
D. Greater than 60%
E. Greater than 80%
, CORRECT ANSWER: B. Greater than 70%
EXPERT RATIONALE: International consensus guidelines recommend a TIR of
greater than 70% (i.e., more than 16.8 hours per day) in the 70–180 mg/dL range for
most people with type 1 or type 2 diabetes as a key CGM metric for optimal
glycemic management.
Q4. Which complication is most closely associated with poor glycemic control
in both type 1 and type 2 diabetes?
A. Hypothyroidism
B. Peripheral neuropathy
C. Osteoporosis
D. Anemia of chronic disease
E. Pulmonary hypertension
CORRECT ANSWER: B. Peripheral neuropathy
EXPERT RATIONALE: Diabetic peripheral neuropathy is one of the most common
complications of chronic hyperglycemia. Sustained high glucose levels lead to nerve
damage through mechanisms including polyol pathway activation, oxidative stress,
and advanced glycation end-product accumulation.
Q5. A patient reports blood glucose levels consistently high in the early
morning before breakfast. What phenomenon is most likely responsible?
A. Somogyi effect
B. Insulin waning
C. Dawn phenomenon
D. Reactive hypoglycemia
E. Glucagon rebound
, CORRECT ANSWER: C. Dawn phenomenon
EXPERT RATIONALE: The dawn phenomenon occurs due to overnight surges in
counter-regulatory hormones (growth hormone, cortisol) that increase hepatic
glucose output, causing fasting hyperglycemia. It is distinguished from the Somogyi
effect (rebound from nocturnal hypoglycemia) by the absence of preceding low
glucose values.
Q6. Which of the following SGLT-2 inhibitors has demonstrated cardiovascular
mortality benefit in patients with established cardiovascular disease and type
2 diabetes?
A. Sitagliptin
B. Metformin
C. Empagliflozin
D. Pioglitazone
E. Exenatide
CORRECT ANSWER: C. Empagliflozin
EXPERT RATIONALE: The EMPA-REG OUTCOME trial demonstrated that
empagliflozin significantly reduced cardiovascular death, hospitalization for heart
failure, and major adverse cardiovascular events in patients with type 2 diabetes
and established cardiovascular disease.
Q7. A 45-year-old woman with type 2 diabetes and stage 3 CKD (eGFR 38
mL/min) is currently on metformin. What is the most appropriate action?
A. Continue metformin at full dose
B. Increase metformin dose to improve glycemic control
C. Discontinue metformin due to lactic acidosis risk
D. Switch to insulin only
